{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "61e507cf",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Cell 1: Install required libraries (run this once if needed)\n",
    "%pip install pandas sentence-transformers scikit-learn"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "c56ab042",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Cell 2: Import necessary modules\n",
    "import pandas as pd\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# Cell 3: Load the Excel file and extract Study Titles\n",
    "df = pd.read_excel('trials_filtered_with_coordinates.xlsx')\n",
    "study_titles = df['Study Title'].tolist()\n",
    "\n",
    "# Cell 4: Load BioBERT model\n",
    "# model = SentenceTransformer('gsarti/biobert-nli')\n",
    "model = SentenceTransformer('neuml/pubmedbert-base-embeddings')\n",
    "\n",
    "# Cell 5: Compute embeddings for study titles\n",
    "study_embeddings = model.encode(study_titles)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "9457099f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Top Matching Study Titles:\n",
      "Study Title: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ‚â• 1%\n",
      "Similarity: 0.7325\n",
      "\n",
      "Study Title: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)\n",
      "Similarity: 0.7190\n",
      "\n",
      "Study Title: Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative\n",
      "Similarity: 0.7000\n",
      "\n",
      "Study Title: Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.6956\n",
      "\n",
      "Study Title: Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer\n",
      "Similarity: 0.6859\n",
      "\n",
      "Study Title: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)\n",
      "Similarity: 0.6697\n",
      "\n",
      "Study Title: A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.6543\n",
      "\n",
      "Study Title: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm\n",
      "Similarity: 0.6487\n",
      "\n",
      "Study Title: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer\n",
      "Similarity: 0.6437\n",
      "\n",
      "Study Title: A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.6342\n",
      "\n",
      "Study Title: A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.6342\n",
      "\n",
      "Study Title: A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na√Øve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\n",
      "Similarity: 0.6332\n",
      "\n",
      "Study Title: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ‚â•50% (MK-3475-D46)\n",
      "Similarity: 0.6258\n",
      "\n",
      "Study Title: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations\n",
      "Similarity: 0.6255\n",
      "\n",
      "Study Title: Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers\n",
      "Similarity: 0.6181\n",
      "\n",
      "Study Title: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)\n",
      "Similarity: 0.6173\n",
      "\n",
      "Study Title: Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC\n",
      "Similarity: 0.6171\n",
      "\n",
      "Study Title: A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.6168\n",
      "\n",
      "Study Title: Phase 2 DoceRamPem for Patients with Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade\n",
      "Similarity: 0.6137\n",
      "\n",
      "Study Title: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.6128\n",
      "\n",
      "Study Title: A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ‚â•50% (MK-1084-004)\n",
      "Similarity: 0.6092\n",
      "\n",
      "Study Title: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)\n",
      "Similarity: 0.6087\n",
      "\n",
      "Study Title: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1\n",
      "Similarity: 0.6058\n",
      "\n",
      "Study Title: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ‚â• 50%) and Without Actionable Genomic Alterations\n",
      "Similarity: 0.6019\n",
      "\n",
      "Study Title: REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)\n",
      "Similarity: 0.6018\n",
      "\n",
      "Study Title: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients\n",
      "Similarity: 0.6008\n",
      "\n",
      "Study Title: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer\n",
      "Similarity: 0.5983\n",
      "\n",
      "Study Title: Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)\n",
      "Similarity: 0.5979\n",
      "\n",
      "Study Title: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ‚â• 50% (MK-2870-007)\n",
      "Similarity: 0.5978\n",
      "\n",
      "Study Title: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer\n",
      "Similarity: 0.5950\n",
      "\n",
      "Study Title: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)\n",
      "Similarity: 0.5932\n",
      "\n",
      "Study Title: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\n",
      "Similarity: 0.5911\n",
      "\n",
      "Study Title: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study\n",
      "Similarity: 0.5903\n",
      "\n",
      "Study Title: A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\n",
      "Similarity: 0.5858\n",
      "\n",
      "Study Title: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors\n",
      "Similarity: 0.5827\n",
      "\n",
      "Study Title: To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations\n",
      "Similarity: 0.5797\n",
      "\n",
      "Study Title: Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Na√Øve Patients With Extensive Stage Small Cell Lung Cancer\n",
      "Similarity: 0.5715\n",
      "\n",
      "Study Title: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer\n",
      "Similarity: 0.5712\n",
      "\n",
      "Study Title: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)\n",
      "Similarity: 0.5677\n",
      "\n",
      "Study Title: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)\n",
      "Similarity: 0.5664\n",
      "\n",
      "Study Title: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer\n",
      "Similarity: 0.5659\n",
      "\n",
      "Study Title: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)\n",
      "Similarity: 0.5604\n",
      "\n",
      "Study Title: MOnaliZumab in Combination with DurvAlumab (MEDI4736) Plus Platinum-based ChemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer\n",
      "Similarity: 0.5554\n",
      "\n",
      "Study Title: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer\n",
      "Similarity: 0.5552\n",
      "\n",
      "Study Title: Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer\n",
      "Similarity: 0.5531\n",
      "\n",
      "Study Title: Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy\n",
      "Similarity: 0.5488\n",
      "\n",
      "Study Title: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment\n",
      "Similarity: 0.5435\n",
      "\n",
      "Study Title: Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer\n",
      "Similarity: 0.5427\n",
      "\n",
      "Study Title: Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer\n",
      "Similarity: 0.5423\n",
      "\n",
      "Study Title: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors\n",
      "Similarity: 0.5420\n",
      "\n",
      "Study Title: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer\n",
      "Similarity: 0.5404\n",
      "\n",
      "Study Title: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC\n",
      "Similarity: 0.5342\n",
      "\n",
      "Study Title: A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer\n",
      "Similarity: 0.5329\n",
      "\n",
      "Study Title: Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer\n",
      "Similarity: 0.5319\n",
      "\n",
      "Study Title: Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer\n",
      "Similarity: 0.5296\n",
      "\n",
      "Study Title: Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC\n",
      "Similarity: 0.5292\n",
      "\n",
      "Study Title: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy\n",
      "Similarity: 0.5286\n",
      "\n",
      "Study Title: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations\n",
      "Similarity: 0.5284\n",
      "\n",
      "Study Title: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01).\n",
      "Similarity: 0.5228\n",
      "\n",
      "Study Title: Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)\n",
      "Similarity: 0.5205\n",
      "\n",
      "Study Title: A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.5204\n",
      "\n",
      "Study Title: Study of Bevacizumab in Combination with Chemoimmunotherapy and Atezolizumab in Patients with Extensive Stage Small Cell Lung Cancer and Liver Metastases\n",
      "Similarity: 0.5199\n",
      "\n",
      "Study Title: Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC\n",
      "Similarity: 0.5194\n",
      "\n",
      "Study Title: Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer\n",
      "Similarity: 0.5187\n",
      "\n",
      "Study Title: Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial\n",
      "Similarity: 0.5179\n",
      "\n",
      "Study Title: Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer\n",
      "Similarity: 0.5158\n",
      "\n",
      "Study Title: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer\n",
      "Similarity: 0.5149\n",
      "\n",
      "Study Title: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.5141\n",
      "\n",
      "Study Title: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)\n",
      "Similarity: 0.5126\n",
      "\n",
      "Study Title: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)\n",
      "Similarity: 0.5115\n",
      "\n",
      "Study Title: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy\n",
      "Similarity: 0.5098\n",
      "\n",
      "Study Title: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation\n",
      "Similarity: 0.5073\n",
      "\n",
      "Study Title: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment\n",
      "Similarity: 0.5039\n",
      "\n",
      "Study Title: Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer\n",
      "Similarity: 0.5036\n",
      "\n",
      "Study Title: A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)\n",
      "Similarity: 0.5009\n",
      "\n"
     ]
    }
   ],
   "source": [
    "\n",
    "# Cell 6: Define user input and compute its embedding\n",
    "cancer_type = \"Non-Small Cell Lung Cancer\"\n",
    "biomarkers = \"Stage 4\"\n",
    "stage = \"EGFR mutation, PD-L1 positive\"\n",
    "user_input = f\"{cancer_type} {biomarkers} {stage}\"\n",
    "user_embedding = model.encode([user_input])[0]\n",
    "\n",
    "# Cell 7: Calculate similarities and find top matches\n",
    "similarities = cosine_similarity([user_embedding], study_embeddings)[0]\n",
    "threshold = 0.5  # Adjust this threshold as needed\n",
    "top_indices = [i for i, sim in enumerate(similarities) if sim >= threshold]\n",
    "top_matches = [(df['Study Title'].iloc[i], similarities[i]) for i in top_indices]\n",
    "top_matches.sort(key=lambda x: x[1], reverse=True)  # Sort by similarity in descending order\n",
    "\n",
    "# Cell 8: Display top matching study titles\n",
    "if top_matches:\n",
    "    print(\"Top Matching Study Titles:\")\n",
    "    for title, sim in top_matches:\n",
    "        print(f\"Study Title: {title}\\nSimilarity: {sim:.4f}\\n\")\n",
    "else:\n",
    "    print(\"No matches found above the threshold.\")\n",
    "    \n",
    "    \n",
    "    \n",
    "# --- Manual Input Section ---\n",
    "\n",
    "# print(\"\\nPlease enter patient information for clinical trial matching.\")\n",
    "\n",
    "# # # --- Example 1: NSCLC, Stage IV, specific mutations ---\n",
    "# user_cancer_type = \"Non-Small Cell Lung Cancer\"\n",
    "# user_stage = \"Stage 4\"\n",
    "# user_biomarkers = \"EGFR mutation, PD-L1 positive\"\n",
    "\n",
    "# find_relevant_trials(df, semantic_trial_embeddings, semantic_index_to_embedding_index,\n",
    "#                      model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "# print(\"\\n\" + \"=\"*80 + \"\\n\") # Separator for multiple searches\n",
    "\n",
    "# # --- Example 2: Breast Cancer, metastatic, HER2-low ---\n",
    "# user_cancer_type = \"Breast Cancer\"\n",
    "# user_stage = \"metastatic\"\n",
    "# user_biomarkers = \"HER2 low\"\n",
    "\n",
    "# find_relevant_trials(df, semantic_trial_embeddings, semantic_index_to_embedding_index,\n",
    "                    #  model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "# print(\"\\n\" + \"=\"*80 + \"\\n\") # Separator for multiple searches\n",
    "\n",
    "\n",
    "# # --- Example 3: Prostate cancer, mCRPC, PSMA positive ---\n",
    "# # Using the example Conditions value directly for high similarity expectation\n",
    "# user_cancer_type = \"Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)\"\n",
    "# user_stage = \"\" # Stage is included in the Conditions text\n",
    "# user_biomarkers = \"\" # Biomarkers are included in the Conditions text\n",
    "\n",
    "# find_relevant_trials(df, semantic_trial_embeddings, semantic_index_to_embedding_index,\n",
    "#                      model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "# print(\"\\n\" + \"=\"*80 + \"\\n\") # Separator for multiple searches\n",
    "\n",
    "# # --- Example 4: Urothelial Carcinoma (from your sample data) ---\n",
    "# user_cancer_type = \"Urothelial Carcinoma\" # Or try 'bladder cancer' in type\n",
    "# user_stage = \"operable high-risk\"\n",
    "# user_biomarkers = \"\" # No specific biomarkers mentioned in the sample brief summary\n",
    "\n",
    "# find_relevant_trials(df, semantic_trial_embeddings, semantic_index_to_embedding_index,\n",
    "#                      model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "# print(\"\\n\" + \"=\"*80 + \"\\n\") # Separator for multiple searches"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
